Cost Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccination Program in Chronic Obstructive Pulmonary Disease Patients Aged 50+ Years in Spain.

Document types check

Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/28409

Title:	Cost Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccination Program in Chronic Obstructive Pulmonary Disease Patients Aged 50+ Years in Spain.
Authors:	Rodríguez González-Moro, Jose Miguel Menéndez, Rosario Campins, Magda Lwoff, Nadia Oyagüez, Itziar Echave, María Rejas, Javier Antoñanzas, Fernando View more
Mesh:	Aged Aged, 80 and over Cost-Benefit Analysis Humans Immunization Programs Middle Aged Pneumococcal Infections Pneumococcal Vaccines Pulmonary Disease, Chronic Obstructive Quality-Adjusted Life Years Spain Vaccination View more
Issue Date:	Jan-2016
Citation:	Clin Drug Investig.2016 Jan;(36)1:41-53
Abstract:	Patients with chronic obstructive pulmonary disease (COPD) are at elevated risk of pneumococcal infection. A 13-valent pneumococcal conjugate vaccine (PCV13) was approved for protection against invasive disease and pneumonia caused by Streptococcus pneumoniae in adults. This study estimated the incremental cost-effectiveness ratio (ICER) of vaccinating COPD patients ≥50 years old with PCV13 compared with current vaccination policy (CVP) with 23-valent pneumococcal polysaccharide vaccine.
PMID:	26547199
URI:	https://hdl.handle.net/20.500.12530/28409
Rights:	openAccess
Appears in Collections:	Fundaciones e Institutos de Investigación > IIS H. General U. Gregorio Marañón > Artículos

Files in This Item:

File	Description	Size	Format
PMC4706838.pdf		952.58 kB	Adobe PDF	View/Open